 |
| April
7, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
- BioCardia: Files Request for Meeting With
FDA to Discuss Accelerated Approval Pathway
for CardiAMP System in Ischemic Heart Failure
More
- Biocom: Section 232
Pharmaceutical Tariffs - Statement More
- CatalYm: Doses First Patient in Phase 2b
Trial Evaluating Visugromab in Combination With
Chemoimmunotherapy as Second-Line Treatment in
Unresectable/Metastatic Hepatocellular
Carcinoma More
- Denali Therapeutics: Regains Full Rights
to Investigational Therapy DNL593 (PTV:PGRN)
for GRN-related Frontotemporal Dementia
(FTD-GRN) More
More
More
More*
- Frazier Life Sciences: Appoints Christian
Schade as Senior Advisor More
- IDEAYA Biosciences: First-Patient-In for
Phase 1 Trial of IDE574, a Potential First-In
Class Dual Inhibitor of KAT6/7 to Target
Multiple Solid Tumor Indications, Including
Breast, Prostate, CRC, and Lung Cancer More
- Outset Medical: Names Derick Elliott as
Executive Vice President of Commercial More
- PinkDx: Publishes Groundbreaking Evidence in
Endometrial Cancer Detection Using a Simple
Vaginal Swab More
- Praxis Precision Medicines: Positive Results
From the EMBRAVE Part A Trial of Elsunersen in
Patients With SCN2A Early-Onset Developmental
and Epileptic Encephalopathy More
- Pulse Biosciences: Enrolls First Patients in
NANOPULSE-AF IDE Pivotal Clinical Study
Evaluating nPulse Cardiac Catheter System for
Atrial Fibrillation More
- SonoNeu: Exits Stealth as Key Part of US
Government-Funded Research Program Worth up
to $41.3M To Advance Sonogenetics Into
Clinic More
- Tenvie Therapeutics: Dosing of First Subject
in Phase 1 Clinical Trial of TNV262, a Fully
CNS-Penetrant NLRP3 Inhibitor More
- Ultragenyx: U.S. FDA Acceptance of BLA
Resubmission for UX111 AAV Gene Therapy to
Treat Sanfilippo Syndrome Type A (MPS IIIA) More
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Exicure: Summary Notice of Pendency and
Proposed Settlement of Stockholder Derivative
Actions More
- Gilead: Will Acquire Tubulis Adding
Potentially Best-in-Class Antibody-Drug
Conjugate and Next Generation Platform to
Further Strengthen Oncology Pipeline More
More
More*
More*
- More on Alameda Startup Emerging From
Stealth With Brain Implant for Stroke Patients
More*
- Neurocrine: Will Acquire Soleno
Therapeutics, Expanding Its Endocrinology
and Rare Disease Portfolio More
More
More*
More*
- Olema Oncology: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- ORIC Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- Profusa: Expands Into Multi-Billion Dollar
Precision Diagnostics Market With $30M Letter
of Intent for a PanOmics Platform More
- Terns Pharmaceuticals: Inducement Grants to
New Employees Under Nasdaq Listing Rule
5635(C)(4) More
|
|
 |
| San
Francisco's most flexible contract
vivarium lab space: Start with a
few cages and grow. |
|
Learn More
→ |
|
|
|
- BioPharmGuy News: Moon Rocket, Fake Masters,
Organ Sacks, Fly Brain, Dead Tortoise More
- Biotech Hangout: Episode 178 Podcast
- Buck Institute: A Small Molecule Drug
Candidate Fully Restores Survival in a Lethal
Mouse Model of a Rare Kidney Stone Disease
That Has No Current Treatment More
- How a Life-Changing Stent Could Help a Palo
Alto Investor Shake Up the Medical Device
Industry More*
- How an Alzheimer’s Risk Gene Disrupts Brain
Circuits Long Before Memory Loss More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- Hiring Outlook: February Brings First YOY
Job Increase Since 2022 More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- Lilly’s Chief Technology Officer Retires
After 35 Years; Astellas Strategy Exec Resigns
More*
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: SFBay Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:SFBay,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
